As per the new swab and viral transport medium market attractiveness analysis of FMI, the global market could reach about US$ 8.86 billion at the end of 2023. The market is projected to register a 5.8% CAGR and top a valuation of US$ 15.60 billion by 2033.
The swab and viral transport medium market has seen a significant increase in demand in recent times, primarily because the number of tests and laboratory investigations has reached an all-time high during the COVID-19 epidemic.
While the pandemic is now driving the market expansion, key players are increasingly focusing on the development of improved testing techniques such as rapid antigen testing and molecular assay studies, which is likely to help to sustain demand over time. In addition, the advancement in diagnosis of these viruses require microbiological culture swab and transport medium to preserve and later identify the viral growth. Thus, the sale of swab and viral transport medium increased to perform these experiments.
The lower and affordable cost of swab and viral transport medium is one of the key aspects contributing to its success across the world. They have become affordable due to assistance from various governmental and nonprofit organizations.
The throat swabs market and the swab and viral transport medium market are closely tied to those for throat swabs. This market covers nasal swabs, buccal swabs, nasopharyngeal swabs, and oropharyngeal swabs in addition to throat swabs. The COVID-19 pandemic is one of several causes driving the demand for throat swabs. The epidemic has resulted in a spike in diagnostic supplies globally, notably throat swabs.
The swab test equipment market and the VTM market are anticipated to continue to develop and change as the need for trustworthy and accurate diagnostic testing increases. Changes in healthcare practices and legislation as well as the continued demand for efficient infectious disease management strategies are what drive both markets. Technology developments, such as the creation of point-of-care testing tools that enable quick and precise diagnosis, have an impact on the sales of swab testing equipment as well.
The leading manufacturers of swab and viral transport medium market are seeking approval for their products in different regions for product launch. It is likely to help in enhancing their product footprint across the globe.
Products that has not been approved in any of the regions, such as North America or Europe, are being evaluated for launch in semi-regulated markets such as India, China, and Brazil, which hold a higher potential for revenue generation. Local manufacturing of swab and viral medium is preferred, over import from leading manufacturing countries amid pandemic crisis. For instance, a real-time PCR kit fused in the detection of SARS-COV-2, which was earlier called 2019-nCoV was launched by Vircell in February 2020.
Different regional manufacturers are focusing for partnerships with larger swab and viral transport medium market players to enhance their product offering in different countries. As a result, there is an increasing demand of swab and viral transport medium seen during the forecast period.
As the demand for COVID-19 testing continues, the swab testing device market has experienced significant growth. As long as there is a demand for testing and diagnosing viral infections, the market is anticipated to keep growing. The creation of novel and cutting-edge swab testing tools, such as those that can deliver quick results or are appropriate for testing at home, is also anticipated to fuel market expansion.
| Attributes | Details |
|---|---|
| Swab and Viral Transport Medium Market Value (2022) | US$ 8.32 billion |
| Swab and Viral Transport Medium Market Value (2023) | US$ 8.86 billion |
| Global Market Absolute Dollar Growth (US$ million/billion) | US$ 587.6 million |
| Swab and Viral Transport Medium Market Value Forecast (2033) | US$ 15.60 billion |
| Swab and Viral Transport Medium Market Projected CAGR (2023 to 2033) | 5.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Market Statistics | Details |
|---|---|
| H1, 2021 (A) | 6.11% |
| H1, 2022 Projected (P) | 6.11% |
| H1, 2022 Outlook (O) | 6.11% |
| BPS Change : H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change : H1, 2022 (O) - H1, 2021 (A) | (-) 06 ↓ |
The global swab and viral transport medium market is expected to decline by 06 basis point share (BPS) in H1-2022 (O) in terms of growth rate when compared with H1-2021. Further comparison of H1-2022 outlook and H1-2022 projected period show the market growth to dip by nearly 10 BPS, according to Future Market Insights' estimate.
The quality control of swabs is not anticipated to be done routinely by frontline laboratories, according to CLSI standard M40-A2. This is one of the primary causes for the drop in BPS. As a result, swabs and VTM from unregistered manufacturers need to be evaluated.
In the global swab and viral transport medium market, FMI gives a comparative study of market growth rates and development prospects. Regulatory approvals and quality system guidelines, as well as the impact of macro and industrial factors, have an impact on the market.
A noteworthy advancement in this industry is the large-scale, in-house manufacturing of viral transport media to assist SARS-COV-2 PCR testing during the COVID-19 pandemic.
In the second half of the projection period, other market categories are expected to do fairly well and have excellent growth possibilities. The establishment of set standard operating procedures for producing viral transport medium is one of the important factors driving the industry's growth.
The swab and viral transport market is forecast to expand at a CAGR of 5.8% during 2023 to 2033 in comparison to a 5.6% CAGR registered from 2018 to 2022. The demand for swab and viral transport medium is increasing significantly due to rapid increase in flu in various regions.
Various governments are also increasing awareness about flu, as well as initiatives undertaken by organizations such as World Health Organization (WHO), Global Alliance for Vaccines and Immunization (GAVI), The Pan American Health Organization (PAHO), etc. These awareness programs are directly linked to the rise in number of testing. For instance, according to 2020 data of HealthyPeople.gov, there are more than 25 million people in the United States suffering from asthma.
The average time required for the manufacturing of swab and viral transport medium and ensuring their availability in the market is around 6 months, however, the swab and viral transport mediums is manufactured and launched in the market in a period of around a few months only (around 3 months).
There are acquisition and collaborations done by the key players in swab and viral transport medium market to improve their presence in other regions of the world. For instance, in June 2018, McKesson Corporation acquired Medical Specialties distributors to support the company's manufacturing services and specialty. This acquisition allowed the company to provide incremental services to other segments of the market also.
The enhanced focus of various government officials across the globe for controlling the spread of infectious diseases can be greatly attributed to the incidence of various pandemics in the past few decades. This is forcing the countries to take preventive and diagnostic measure to limit their outbreak, especially that of the influenza, Adenovirus, coronavirus pandemic. During the forecast period, the market is expected to present several growth opportunities.
These factors are anticipated to support about a 1.8X increase in the swabs and viral transport medium market between 2023 and 2033. The market is projected to be worth US$ 15.60 billion by the end of 2033, according to FMI analysts.
Principal Consultant
The growth of the swab and viral transport medium market is limited by unfavorable regulatory scenarios which limit the expansion of regional players in the market. In addition, the unpredictable nature of seasonal influenza and other infections varied largely estimated by WHO which occasionally are exaggerated that could lead to create demand and supply gap.
The uncertain nature of the incidence of the infections has led to the adoption of a conservative approach by various test-manufacturing companies that leads to lower supply even in the pandemic or follow-up outbursts. These factors are hampering the growth of the market during the forecast period by 2030.
The manufacturers have great opportunity to grow in this swab and viral transport medium market by increasing awareness about the importance of testing for infection detection across the world. This is likely to create significant revenue-generation opportunities during the forecast period from 2022 to 2030.
Different governmental and non-governmental organizations (NGOs) put extra efforts to spread awareness and create swabs and viral transport medium in developing and underdeveloped nations, which is also expected to boost the market. For instance, in May 2020, Sree Chitra Triunal Institute for Medical Sciences and Technology (SCTIMST) which comes under the DST, Government of India, developed two types of swabs and viral transport medium from nasal and oral for COVID-19 testing. Thus, similar activities by other organizations can create further opportunities for the swab and viral transport medium manufacturers in the coming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | United States |
|---|---|
| CAGR % 2018 to 2022 | 5.4% |
| CAGR % 2023 to End of Forecast(2033) | 6.1% |
| Market Size by End of Forecast Period(2033) | US$ 7,091.2 million |
| Country | Germany |
|---|---|
| CAGR % 2018 to 2022 | 6.8% |
| CAGR % 2023 to End of Forecast(2033) | 6.7% |
| Market Size by End of Forecast Period(2033) | US$ 1,011.2 million |
| Country | United Kingdom |
|---|---|
| CAGR % 2018 to 2022 | 5.3% |
| CAGR % 2023 to End of Forecast(2033) | 5.9% |
| Market Size by End of Forecast Period(2033) | US$ 648.2 million |
| Country | China |
|---|---|
| CAGR % 2018 to 2022 | 7.3% |
| CAGR % 2023 to End of Forecast(2033) | 7.7% |
| Market Size by End of Forecast Period(2033) | US$ 560.8 million |
| Country | Canada |
|---|---|
| CAGR % 2018 to 2022 | 5.4% |
| CAGR % 2023 to End of Forecast(2033) | 4.0% |
| Market Size by End of Forecast Period(2033) | US$ 366.4 million |
The United States swab and viral transport medium market emerged as the leading market. This is primarily due to the enhancement in the availability of new diagnostic tests and drugs as over-the-counter (OTC) products in pharmacies and retail shops in the country to support the American population to fight against the COVID-19. For instance, in December 2020, the Ellume COVID-19 Home Test gained the United States Food and Drug Administration approval for an emergency use authorization (EUA) as the first over-the-counter (OTC) fully at-home diagnostic test for COVID-19.
The extensive testing infrastructure in the country, which has been instrumental in the early detection and containment of infectious diseases, also drives market growth. Also, the COVID-19 pandemic has expedited the nation's need for better swabs and viral delivery media. With the large-scale testing and vaccination campaigns underway, the need for reliable and efficient sample collection and transportation methods has become paramount.
The United States is home to several leading manufacturers and suppliers of swab and viral transport mediums. With the sake of raising the caliber and effectiveness of their products, many businesses have made large investments in research and development. They are thus in high demand in the global market. In addition, rise in rapid product capabilities and increased manufacturing capacity of the swab and viral transport medium manufacturers also contributed into the growth of the market.
The key factor influencing the Germany swab and viral transport medium market is the country’s robust healthcare system. It places a high value on quality medical supplies and technologies. German consumers have a high demand for premium swabs and viral transport mediums, making the country a valuable market for producers and suppliers. Furthermore, Germany's sizable and expanding population adds to the country's market appeal for items like viral transport mediums and swabs. With a population of more than 84 million, the nation serves as a substantial market for medical equipment and supplies.
Several notable institutions and research centers are located in Germany. For their numerous scientific investigations and clinical trials, these call for dependable and top-notch swabs and viral transport mediums. Germany's market is impacted by its strict regulatory environment. To guarantee the efficacy and safety of medicinal items, the nation has strict rules in place. This fosters an atmosphere that is advantageous for suppliers and manufacturers that uphold these high standards.
The key players of the country are primarily involved in acquiring other brands for improving their presence with wider product portfolio and geographic presence and increased product capabilities, which helped them in providing improved manufacturing capacity of the swab and viral transport medium. For instance, in February 2020, the Deltalab Group had acquired a bulk stake in the shareholders of Equilabo Scientific Company. This acquisition helped the Deltalab group to enhance their offerings from Equilabo’s specialty.
The China swab and viral transport medium market is fueled by a multitude of factors. The COVID-19 pandemic, which has raised the demand for diagnostic testing and screening procedures, has been one of the main triggers. Swabs and viral transport mediums are particularly in demand as a result of this. In addition to the pandemic, disease prevention and control have received more attention in China. The need for medical equipment and supplies has increased as a result.
The increasing prevalence of chronic and infectious diseases in China has created a need for diagnostic tools to facilitate accurate and timely diagnoses. Moreover, the rapid growth of the population coupled with the aging demographic has increased the need for medical supplies and equipment, including swabs and viral transport mediums. As a result, the demand for these products has been on the rise.
Due to increasing number of people suffering from flu, the demand for swab and viral transport medium increases to test and confirm the type of viral infection. According to Nature publication by Jing Li, Yinzi Chen, Xiling Wang & Hongjie Yu, 122.79 per 100,000 persons in China suffered from influenza, it being the main reason associated with the high mortality rates.
The market in the United Kingdom is primarily driven by the demand for diagnostic testing for infectious diseases. The COVID-19 pandemic has caused a huge increase in demand and market growth. The market expansion has been further supported by the rising awareness among medical professionals of the significance of employing high-quality swabs and viral transport mediums for accurate diagnosis and disease management.
The demand for swabs and VTMs is likely to remain high as the government in the United Kingdom continues its effort to control the spread of any other viruses. The growing demand for these items has been influenced by proactive steps taken by the government and commercial healthcare organizations to improve illness surveillance and extend testing capabilities. To assure sufficient supplies for testing, they also pushed to enhance the manufacturing and distribution of these items. Therefore, the market is likely to continue to grow owing to the ongoing need for infectious disease testing and surveillance.
The Canada swab and viral transport medium market has witnessed significant growth during the COVID-19 pandemic. Swab and viral transport media, which are essential for gathering and transferring samples for COVID-19 testing, have seen an increase in demand as a result of the need for COVID-19 testing.
The Canadian government has also made investments in local production capacity to solve the scarcity of swabs and viral delivery media. In May 2020, the government announced US$ 4 million funding in for a project led by SQI Diagnostics to build a Canada-made COVID-19 test kit, which contains a swab and viral transport medium.
Swabs and viral transport media are also employed in other diagnostic tests, such as those for influenza and other respiratory disorders, in addition to COVID-19 testing. This implies that there could probably still be a market for these goods even after the COVID-19 epidemic has passed.
The key manufacturers are expanding their business in the country to meet the rising demand of the swab and viral transport medium of increasing population with infectious diseases. India provides great opportunity to enhance the distribution of products due to its large population affected by COVID-19 since 2020.
| Segment | Product |
|---|---|
| Attributes | Viral Swabs |
| CAGR % 2018 to 2022 | 5.9% |
| CAGR % 2023 to End of Forecast(2033) | 8.8% |
| Segment | End-user |
|---|---|
| Attributes | Hospitals & ASCs |
| CAGR % 2018 to 2022 | 5.9% |
| CAGR % 2023 to End of Forecast(2033) | 6.6% |
Viral swabs are a highly popular product type in the market owing to their vital function in the diagnosis of viral infections. These swabs are made to effectively capture and preserve viral samples from patients so they can be taken to a lab and examined there. Swabs have improved significantly over time, with developments such as double-ended flocked swabs, kits with integrated vials, and so on, all of which have aided the expansion of the swab and viral transport medium market. Virus swab increased the frequency of detection of each respiratory virus.
In this regard, other types of swabs for various infections, which including nasal swabs, nasopharyngeal swabs, and throat swabs, are likely to continue to provide significant income potential which leads to account for top share in the market. Viral swabs are widely used because of their accuracy and ease to use. They are more successful at gathering samples than other kinds of swabs since they are particularly made to target virus particles in the body.
The COVID-19 pandemic has significantly raised the demand for viral swabs, which has increased the need for rapid and reliable viral testing. The nasopharyngeal swabs market, as a result, experienced significant growth during that period. To accommodate the rising demand, manufacturers have increased the output of viral swabs and transport media.
The deep nasal swabs market, a part of the larger viral swabs market, also witnessed rapid growth, particularly in response to the COVID-19 pandemic. Deep nasal swabs have been extensively used in testing for COVID-19 owing to their high precision and capability to detect the virus in asymptomatic individuals.
Hospitals & ASCs are the principal healthcare institutions where patients with suspected or proven infectious diseases are treated. This is predominantly seen owing to the high number of patient visits in hospitals & ASCs suffering from viral diseases for seeking treatment, rising the demand for swab and viral transport medium for proper diagnosis. These institutions are frequently in charge of testing and diagnosing infectious diseases. They are typically the initial point of contact for individuals seeking medical assistance.
Hospitals & ASCs require a consistent supply of swabs and viral transport medium to collect and transport samples for testing. The culture swab market, therefore, has seen steady growth lately, driven by the rise in demand for diagnostic testing and the increasing occurrence of infectious diseases. Cultural swabs are widely used in hospitals, clinics, and laboratories for the diagnosis of bacterial and viral infections.
Hospitals & ASCs are also in charge of treating patients who have been identified as having infectious diseases. They need to have the tools on hand to promptly identify and treat patients as well as safeguard healthcare professionals from potential infectious agent exposure. Therefore, the swabs and viral transport mediums are primarily distributed to hospitals & ASCs to guarantee the prompt and correct diagnosis of infections.
Adenoviruses are commonly observed viruses that cause a range of illness including cold-like symptoms, fever, sore throat, bronchitis, and others. On the other hand, Varicella zoster virus are responsible for causing highly contagious disease such as chicken pox. Therefore, to diagnose or treat these illnesses, proper detection of these viruses are required that can be done using swab and viral transport medium. Thereby, leading to account for top share in the market by application.
Companies in the swab and viral transport medium market are pursuing new product innovation and launches, regulatory approvals and company expansions as the key strategies.
Key manufacturers are aiming on development of advance and cost effective products, establishing distribution agreement to increase geographic presence, especially in developing or emerging region. In addition, they are targeting Asia Pacific region by establishing manufacturing unit in order to reduce manufacturing cost.
Top Market Players and their Recent Developments in Swab and Viral Transport Medium Market
Cardinal Health: It provides performance and data solutions for healthcare institutions, distributes medications, and produces and distributes medical and laboratory items. Moreover, it runs cyclotron and nuclear pharmacies, as well as produces its own range of privately branded medical and surgical supplies. Logistics, product, business, and patient solutions make up its four main areas of specialization. Retail clients such as chain and independent pharmacies, pharmacy stores in mass merchandisers and supermarkets, hospitals, ambulatory care facilities, doctor's offices, clinical labs, and alternative healthcare providers are among its clientele.
McKesson Corp (McKesson): Pharmaceutical distribution, healthcare services, and information technology solutions are all offered by McKesson. The business sells prescription medications, medical supplies, and cosmetics. Moreover, it provides pharmacy operations, automation solutions, medication buying management, pharmacy group purchasing, reimbursement for pharmacy claims, audit risk mitigation, patient adherence and wellness, alternate site pharmacy solutions, pharmacy consulting, and pharmacy technology. McKesson provides medical-surgical solutions to healthcare professionals as well as pharmaceutical and specialty solutions to retail, hospital, alternate site, and participating pharmacies in the United States that operate under franchise agreements and brand partnerships.
Becton, Dickinson, and Company (BD): Through enhancing medical discovery, diagnostics, and care delivery, BD, one of the significant global providers of medical technology, is transforming the world of healthTM. By creating cutting-edge technology, services, and solutions that increase both clinical processes for healthcare practitioners and clinical therapy for patients, the firm helps the unsung heroes on the front lines of healthcare. To tackle a variety of difficult global health concerns, BD collaborates with organizations all over the world and has a presence in nearly every nation.
The market is expected to generate revenue of US$ 8.86 billion in 2023.
The growth potential for swab and viral transport medium is 5.8% CAGR.
The market expanded at a CAGR of 5.6% in the historical period.
Surging demand for precision diagnostics is determining the market growth.
Thermo Fisher Scientific Inc., Quidel Corporation, and COPAN Diagnostics Inc. are active key players in the market.
1. Executive Summary | Swab and Viral Transport Medium Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Swab Type 5.3.1.1. Nasal Swabs 5.3.1.2. Nasopharyngeal Swabs 5.3.1.3. Throat Swabs 5.3.2. Transport Medium 5.3.2.1. Tissue Culture Medium 5.3.2.2. Glycerol Transport Medium 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Viral Infection Diagnosis 6.3.1.1. COVID-19 6.3.1.2. Influenza 6.3.1.3. Herpes Simplex Virus 6.3.1.4. Varicella-zoster Virus 6.3.1.5. Others 6.3.2. Other Applications 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033 7.3.1. Hospitals & Clinics 7.3.2. Microbiology Laboratories 7.3.3. Diagnostic Laboratories 7.4. Y-o-Y Growth Trend Analysis By End User , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Type 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Type 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Type 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Type 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Type 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Type 14.2.3. By Application 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By Application 14.3.4. By End User 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Type 15.2.3. By Application 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Type 15.3.3. By Application 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Type 16.1.2.2. By Application 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Type 16.2.2.2. By Application 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Type 16.3.2.2. By Application 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Type 16.4.2.2. By Application 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Type 16.5.2.2. By Application 16.5.2.3. By End User 16.6. United kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Type 16.6.2.2. By Application 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Type 16.7.2.2. By Application 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Type 16.8.2.2. By Application 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Type 16.9.2.2. By Application 16.9.2.3. By End User 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Type 16.10.2.2. By Application 16.10.2.3. By End User 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Type 16.11.2.2. By Application 16.11.2.3. By End User 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Type 16.12.2.2. By Application 16.12.2.3. By End User 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Type 16.13.2.2. By Application 16.13.2.3. By End User 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Type 16.14.2.2. By Application 16.14.2.3. By End User 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Type 16.15.2.2. By Application 16.15.2.3. By End User 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Type 16.16.2.2. By Application 16.16.2.3. By End User 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Type 16.17.2.2. By Application 16.17.2.3. By End User 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Type 16.18.2.2. By Application 16.18.2.3. By End User 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Type 16.19.2.2. By Application 16.19.2.3. By End User 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Type 16.20.2.2. By Application 16.20.2.3. By End User 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Type 16.21.2.2. By Application 16.21.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Type 17.3.3. By Application 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Thermo Fisher Scientific 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Becton 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Dickinson and Company 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. MWE 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Titan Biotech Ltd 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. COPAN Diagnostics Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. MANTACC 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Puritan Medical Products 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. YOCON Biology 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Trinity Biotech 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. VIRCELL S.L. 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Swab and Viral Transport Medium Market
